August 31st 2020
By Deana Ferreri, PhD
Health technology tssessments play an important role in building confidence for use of biosimilars, yet very few meet criteria for thoroughness.
By Tony Hagen
For all intents and purposes, Semglee is a biosimilar insulin, but official biosimilar status is needed to clinch the marketing aspect.
August 26th 2020
By Skylar Jeremias
Opinion leaders discuss the significance of regulatory changes affecting biosimilar and insulin products.
August 25th 2020
The statistics show that for the Rocky Mountain province, biosimilar savings are pouring into the health care system and allowing for significantly greater access.
August 18th 2020
A postmarketing surveillance study of Omnitrope in pediatric patients with growth hormone deficiency sheds new light on how this agent performs relative to its reference product.
August 17th 2020
A Pacific Research Institute economist says that by his scorecard, biosimilars are not supercharging the market the way they ought to be doing .
August 15th 2020
There has been an outpouring of advocacy tugging biosimilars into the marketplace, and market share of these lower-cost drugs has increased.
August 5th 2020
Biosimilars have improved access to health care in India, but many effective new drugs are high priced and patented, and authors of a new study recommend interventions to make these available, too.
August 1st 2020
Although the pandemic continues to affect health care companies worldwide, biosimilar manufacturers continue to move forward with new product developments and business plans.
July 31st 2020
Vizient predicts that drug price inflation, partly due to the coronavirus disease 2019 (COVID-19), will be 3.29% in 2021 and is banking on biosimilars to help contain the rising cost of medication, it said in a comprehensive review for its member health companies.
